Live Kidney Donor Study

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Completed
CT.gov ID
NCT00608283
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH), Health Resources and Services Administration (HRSA) (U.S. Fed)
8,951
3
46
2983.7
64.9

Study Details

Study Description

Brief Summary

Kidney transplants from living donors now account for 40% of all the kidney transplants done in the United States. However, the current information on how donating a kidney can affect the donor's long term health needs further investigation. The purpose of this study is to collect data on a large number of live kidney donors and create and analyze a comprehensive database. Information about the number of living kidney donors, including those who have experienced kidney failure, heart problems, and death will be gathered for the database. Investigators will then use the database to identify the risks of kidney failure, associated conditions, and death after living donation. The database will also be used to identify characteristics that put donors at higher risk for health problems after donation.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Kidney transplantation is the preferred treatment to dialysis for most people with kidney failure. However, the current waiting time to receive a kidney from a deceased donor is greater than 5 years in some parts of the United States. Kidneys from living donors have increased the number of kidneys available for transplantation and decreased the waiting period for those needing a transplant. Living kidney donation also provides several advantages over deceased donor kidneys, including more timely transplantation and longer function of the transplanted kidney. Despite these facts, there is inadequate information about whether living kidney donation may have serious adverse effects on the donor's health. Long-term data on the health risks of living donation are needed.

    The purpose of this study is to establish and analyze a database of information on living donors who have or are going to donate a kidney at three transplant centers with longstanding live kidney donation programs through June 2011. Donor and recipient characteristics as well as specific data on kidney failure, heart disease, and death will be collected. National databases such as the Scientific Registry of Transplant Recipients, the Social Security Death Master File, the National Death Index and records maintained by the Centers for Medicare and Medicaid Services for patients with end stage renal disease (ESRD) will be used to supplement data provided by the participating transplant centers. After establishing the database, researchers expect to 1) determine the long-term risk of live kidney donation and 2) identify donor characteristics associated with higher risk for health problems after donation. Death, cause of death, and incidence of ESRD will be compared to those rates reported by the Centers for Disease Control and Prevention for the U.S. population during the same time period.

    There will be no study visits for this study. Investigators will gather data from the medical charts of all live kidney donors from the three transplant centers through June 2011.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    8951 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Live Kidney Donor Study (RELIVE-01)
    Study Start Date :
    Aug 1, 2007
    Actual Primary Completion Date :
    Jun 1, 2011
    Actual Study Completion Date :
    Jun 1, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    Live Kidney Donors

    People who are going to donate a kidney at one of the three transplant centers from August 2007 until June 2011

    Outcome Measures

    Primary Outcome Measures

    1. Overall mortality [Throughout study]

    2. Cause-specific mortality [Throughout study]

    3. End stage renal disease as defined in the protocol [Throughout study]

    Secondary Outcome Measures

    1. Cardiovascular and renal morbidity [Throughout study]

    2. 6 months incidence of adverse events [At 6 months after kidney donation]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Donated kidney at one of the three participating study centers
    Exclusion Criteria:
    • None

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alabama at Birmingham Birmingham Alabama United States 35294
    2 University of Minnesota Minneapolis Minnesota United States 55455
    3 Mayo Clinic Rochester Minnesota United States 55905

    Sponsors and Collaborators

    • National Institute of Allergy and Infectious Diseases (NIAID)
    • National Heart, Lung, and Blood Institute (NHLBI)
    • Health Resources and Services Administration (HRSA)

    Investigators

    • Principal Investigator: Sandra J. Taler, MD, Division of Nephrology and Hypertension, Mayo Clinic
    • Principal Investigator: Clifton Kew, MD, University of Alabama at Birmingham
    • Principal Investigator: Hassan Ibrahim, MD, University of Minnesota

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Institute of Allergy and Infectious Diseases (NIAID)
    ClinicalTrials.gov Identifier:
    NCT00608283
    Other Study ID Numbers:
    • DAIT RELIVE-01
    First Posted:
    Feb 6, 2008
    Last Update Posted:
    Mar 27, 2017
    Last Verified:
    Mar 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 27, 2017